A 16-week multicenter, 2-period study to investigate the effect of the combination of fluvastatin ER [extended-release] 80mg and fenofibrate 200mg on HDL-C [high density lipoprotein cholesterol] in comparison to the combination of simvastatin 20mg and ezetimibe 10mg in patients with metabolic syndrome.

Trial Profile

A 16-week multicenter, 2-period study to investigate the effect of the combination of fluvastatin ER [extended-release] 80mg and fenofibrate 200mg on HDL-C [high density lipoprotein cholesterol] in comparison to the combination of simvastatin 20mg and ezetimibe 10mg in patients with metabolic syndrome.

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Fluvastatin (Primary) ; Ezetimibe; Fenofibrate; Simvastatin
  • Indications Metabolic syndrome
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 07 Nov 2011 Actual end date (Mar 2007) added as reported by ClinicalTrials.gov.
    • 21 Mar 2008 Status changed from in progress to completed, as reported by ClinicalTrials.gov.
    • 13 Dec 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top